{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:56:09Z","timestamp":1792616169459,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2311201"],"award-info":[{"award-number":["2024YFC2311201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jinf.2026.106840","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:33:07Z","timestamp":1788676387000},"page":"106840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk stratification for tuberculosis reactivation in patients receiving biological and non-biological immunomodulators: A review of current literature"],"prefix":"10.1016","volume":"93","author":[{"given":"Qiaoling","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingluan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ci","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8696-784X","authenticated-orcid":false,"given":"Jingyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8001-6049","authenticated-orcid":false,"given":"Zenghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-0747","authenticated-orcid":false,"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106840_bib1","first-page":"25","article-title":"Host Cell Death and Modulation of Immune Response against Mycobacterium tuberculosis Infection","author":"Vu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jinf.2026.106840_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146704","article-title":"Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis","volume":"14","author":"Grifoni","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1244556","article-title":"Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences","volume":"14","author":"Aiello","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fcimb.2012.00145","article-title":"Mycobacterial signaling through toll-like receptors","volume":"2","author":"Basu","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jinf.2026.106840_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097515","article-title":"Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8\u207a T cells","volume":"9","author":"Harriff","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2026.106840_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820134","article-title":"the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses","volume":"13","author":"Cronan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/IAI.68.2.577-583.2000","article-title":"Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice","volume":"68","author":"Pedrosa","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2026.106840_bib8","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/IAI.70.8.4591-4599.2002","article-title":"Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils","volume":"70","author":"Kisich","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2026.106840_bib9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/IAI.72.3.1804-1806.2004","article-title":"Rat neutrophils prevent the development of tuberculosis","volume":"72","author":"Sugawara","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2026.106840_bib10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1189\/jlb.68.6.897","article-title":"Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction","volume":"68","author":"Xing","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jinf.2026.106840_bib11","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1128\/IAI.00381-07","article-title":"Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy","volume":"75","author":"Schierloh","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2026.106840_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/infdis\/jiy034","article-title":"Interleukin-21 Regulates Natural Killer Cell Responses During Mycobacterium tuberculosis Infection","volume":"217","author":"Paidipally","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.172.1.130","article-title":"NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen","volume":"172","author":"Vankayalapati","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib14","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.176.4.2610","article-title":"Human NK cells positively regulate gammadelta T cells in response to Mycobacterium tuberculosis","volume":"176","author":"Zhang","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jinf.2026.106840_bib15","article-title":"Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention","volume":"2024","author":"Zhuang","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.jinf.2026.106840_bib16","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1126\/science.7690989","article-title":"A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma","volume":"261","author":"Shuai","year":"1993","journal-title":"Science."},{"key":"10.1016\/j.jinf.2026.106840_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","article-title":"Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions","volume":"76","author":"Shuai","year":"1994","journal-title":"Cell."},{"key":"10.1016\/j.jinf.2026.106840_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.175.4.1111","article-title":"Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages","volume":"175","author":"Chan","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.jinf.2026.106840_bib19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1496401","article-title":"Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor","volume":"257","author":"Schindler","year":"1992","journal-title":"Science."},{"key":"10.1016\/j.jinf.2026.106840_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109696","article-title":"CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection","volume":"36","author":"Lu","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.165.1.353","article-title":"CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages","volume":"165","author":"Serbina","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/648735","article-title":"Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results","volume":"201","author":"Babu","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0006-2016","article-title":"Regulation of Immunity to Tuberculosis","volume":"4","author":"Brighenti","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jinf.2026.106840_bib24","first-page":"191","article-title":"Selective Localization of Pulmonary Emboli: An Explanation for the Apical Localization of Reinfection Tuberculosis","volume":"61","author":"Smith","year":"1949","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.jinf.2026.106840_bib25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/jb.91.2.718-724.1966","article-title":"Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and nonvaccinated animals","volume":"91","author":"Smith","year":"1966","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jinf.2026.106840_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1472-9792(02)00079-3","article-title":"Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles","volume":"83","author":"McMurray","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"issue":"439-46","key":"10.1016\/j.jinf.2026.106840_bib27","article-title":"Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination","volume":"24","author":"Cohen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jinf.2026.106840_bib28","first-page":"24","article-title":"Prolonged B-Lymphocyte-Mediated Immune and Inflammatory Responses to Tuberculosis Infection in the Lungs of TB-Resistant Mice","author":"Linge","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jinf.2026.106840_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.750068","article-title":"Pleiotropic Effect of IL-6 Produced by B-Lymphocytes During Early Phases of Adaptive Immune Responses Against TB Infection","volume":"13","author":"Linge","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib30","first-page":"S225","article-title":"B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. Clin Infect Dis","volume":"613","author":"Rao","year":"2015"},{"key":"10.1016\/j.jinf.2026.106840_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1494283","article-title":"Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents","volume":"16","author":"Picchianti-Diamanti","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jinf.2026.106840_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jinf.2026.106840_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-022-02821-x","article-title":"Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study","volume":"24","author":"Zeng","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jinf.2026.106840_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/annrheumdis-2019-216128","article-title":"Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO)","volume":"79","author":"Pettipher","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2026.106840_bib37","article-title":"Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study","volume":"8","author":"Zingaropoli","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.jinf.2026.106840_bib38","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.jinf.2026.106840_bib39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2007.06.010","article-title":"High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients","volume":"32","author":"Au","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.jinf.2026.106840_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jjco\/hyw146","article-title":"Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"47","author":"Ishizawa","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jinf.2026.106840_bib41","doi-asserted-by":"crossref","first-page":"978","DOI":"10.24953\/turkjped.2021.06.005","article-title":"Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases","volume":"63","author":"\u00d6zl\u00fc","year":"2021","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.jinf.2026.106840_bib42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/ijd.13337","article-title":"Long-term efficacy and safety of anakinra in a patient with Beh\u00e7et's disease and concomitant tuberculosis infection","volume":"56","author":"Emmi","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jinf.2026.106840_bib43","first-page":"734","article-title":"Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra","volume":"33","author":"Migkos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)","volume":"13","author":"Settas","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib45","article-title":"Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era","volume":"8","author":"Campbell","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jinf.2026.106840_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jinf.2026.106840_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ibd\/izad032","article-title":"Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study","volume":"30","author":"Liu","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib48","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e107","article-title":"The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea","volume":"37","author":"Choi","year":"2022","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jinf.2026.106840_bib49","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jdv.16460","article-title":"Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials","volume":"34","author":"Puig","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jinf.2026.106840_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jdcr.2017.02.001","article-title":"Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis","volume":"3","author":"Lynch","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib51","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2012.2958","article-title":"Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment","volume":"148","author":"S\u00e1nchez-Moya","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jinf.2026.106840_bib52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","volume":"168","author":"Tsai","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jinf.2026.106840_bib53","first-page":"1233","article-title":"Advances in research on the safety of secukinumab in terms of tuberculosis infection in the treatment of spinal arthitis-related diseases, Chin","volume":"32","author":"Song","year":"2023","journal-title":"J New Drugs"},{"key":"10.1016\/j.jinf.2026.106840_bib54","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jinf.2026.106840_bib55","first-page":"1491","article-title":"Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-\u03b1 inhibitors: a nationwide nested case-control analysis","volume":"41","author":"Kim","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1046306","article-title":"Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review","volume":"14","author":"Jahnich","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jinf.2026.106840_bib57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.jinf.2026.106840_bib58","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-\u03b1 Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry\/Cohort Studies","volume":"42","author":"Ai","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib59","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s10067-019-04866-x","article-title":"Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review","volume":"39","author":"Sartori","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib60","article-title":"Risk of tuberculosis disease in patients receiving TNF-\u03b1 antagonist therapy: A meta-analysis of randomized controlled trials","volume":"62","author":"Khelghati","year":"2024","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.jinf.2026.106840_bib61","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: A Review in Rheumatoid Arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs."},{"key":"10.1016\/j.jinf.2026.106840_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-020-02399-2","article-title":"Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jinf.2026.106840_bib63","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jinf.2026.106840_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00393-022-01274-6","volume":"82","author":"Rath","year":"2023","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jinf.2026.106840_bib66","first-page":"Cd010699","article-title":"Belatacept for kidney transplant recipients","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jinf.2026.106840_bib67","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jinf.2026.106840_bib69","article-title":"Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jinf.2026.106840_bib70","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/ibd\/izac269","article-title":"Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study","volume":"29","author":"Lin","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib71","article-title":"Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2021.05.034","article-title":"Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study","volume":"158","author":"Kim","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jinf.2026.106840_bib73","first-page":"260","article-title":"Tuberculous Lymphadenitis in a Patient Receiving PD-1 Inhibitor for Melanoma: A Case Report and Brief Literature Review. Current","volume":"28","author":"Baran","year":"2021","journal-title":"Oncology."},{"key":"10.1016\/j.jinf.2026.106840_bib74","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13256-021-02900-8","article-title":"Ganglionar tuberculosis infection evolving to hemophagocytic lymphohistiocytosis after anti-programmed cell death 1 treatment for high-risk melanoma: a case report","volume":"15","author":"Costa","year":"2021","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib75","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1186\/s12879-021-06845-7","article-title":"Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report","volume":"21","author":"Lau","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib76","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02512-2021","article-title":"The paradox of immune checkpoint inhibition re-activating tuberculosis","volume":"60","author":"Ahmed","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2026.106840_bib77","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/thoraxjnl-2021-217575","article-title":"Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"77","author":"Zhu","year":"2022","journal-title":"Thorax."},{"key":"10.1016\/j.jinf.2026.106840_bib78","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00262-021-02905-8","article-title":"Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area","volume":"70","author":"Stroh","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jinf.2026.106840_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jinf.2026.106840_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jinf.2026.106840_bib81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12664-023-01434-9","article-title":"Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis - An Indian multicentric experience","volume":"43","author":"Giri","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jinf.2026.106840_bib82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CM9.0000000000002561","article-title":"Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jinf.2026.106840_bib83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: A systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jinf.2026.106840_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2509","article-title":"Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients","author":"Polverelli","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jinf.2026.106840_bib85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jinf.2026.106840_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.654","article-title":"Drug-induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis","volume":"8","author":"Tani","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5045\/br.2019.54.2.151","article-title":"First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia","volume":"54","author":"Kim","year":"2019","journal-title":"Blood Res"},{"key":"10.1016\/j.jinf.2026.106840_bib88","doi-asserted-by":"crossref","first-page":"E709","DOI":"10.21037\/jtd.2017.07.31","article-title":"A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non-small cell lung cancer","volume":"9","author":"Lee","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell."},{"key":"10.1016\/j.jinf.2026.106840_bib90","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/eji.201546259","article-title":"Rewiring cellular metabolism via the AKT\/mTOR pathway contributes to host defence against Mycobacterium tuberculosis in human and murine cells","volume":"46","author":"Lachmandas","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jinf.2026.106840_bib91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/tid.12555","article-title":"Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use","volume":"18","author":"Guirao-Arrabal","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3904\/kjim.2015.121","article-title":"Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma","volume":"32","author":"Jeon","year":"2017","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jinf.2026.106840_bib93","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jinf.2026.106840_bib94","doi-asserted-by":"crossref","first-page":"e00253","DOI":"10.1128\/mBio.00253-15","article-title":"Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria","volume":"6","author":"Moreira","year":"2015","journal-title":"mBio."},{"key":"10.1016\/j.jinf.2026.106840_bib95","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1080\/07391102.2020.1852966","article-title":"Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics","volume":"40","author":"Mahfuz","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jinf.2026.106840_bib96","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fmicb.2017.00746","article-title":"Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome","volume":"8","author":"Moreira","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jinf.2026.106840_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02307-16","article-title":"Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome","volume":"61","author":"Moreira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2026.106840_bib98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5045\/br.2013.48.1.35","article-title":"Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma","volume":"48","author":"Ahn","year":"2013","journal-title":"Blood Res"},{"key":"10.1016\/j.jinf.2026.106840_bib99","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5045\/br.2013.48.3.233","article-title":"Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma","volume":"48","author":"Kim","year":"2013","journal-title":"Blood Res"},{"key":"10.1016\/j.jinf.2026.106840_bib100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12185-013-1270-7","article-title":"Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens","volume":"97","author":"Jung","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jinf.2026.106840_bib101","first-page":"152","article-title":"Analysis on related factors of pulmonary infection in patients with multiple Myeloma Treated with Bortezomib","volume":"29","author":"Li","year":"2021","journal-title":"J Exp Hematol"},{"key":"10.1016\/j.jinf.2026.106840_bib102","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.3747\/co.27.5577","article-title":"Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre","volume":"27","author":"Gitman","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jinf.2026.106840_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.15006","article-title":"Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: A population-based study","volume":"75","author":"Ting","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jinf.2026.106840_bib104","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.transproceed.2013.12.024","article-title":"Comparison of tuberculosis infection rates in a national database of renal transplant patients with data from a single center in Taiwan","volume":"46","author":"Chen","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jinf.2026.106840_bib105","first-page":"19","article-title":"Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India","author":"Agarwal","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib106","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1399-3062.2012.00721.x","article-title":"Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients","volume":"14","author":"Ha","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jinf.2026.106840_bib107","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.transproceed.2004.08.114","article-title":"Various clinical presentations of tuberculosis in heart transplant recipients","volume":"36","author":"Chou","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jinf.2026.106840_bib108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0377-1237(09)80047-6","article-title":"Renal Transplantation: Experience at a Single Centre","volume":"65","author":"Murty","year":"2009","journal-title":"Medical Journal Armed Forces India"},{"key":"10.1016\/j.jinf.2026.106840_bib109","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.transproceed.2008.07.034","article-title":"Tuberculosis in Thai renal transplant recipients: a 15-year experience","volume":"40","author":"Rungruanghiranya","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jinf.2026.106840_bib110","doi-asserted-by":"crossref","first-page":"20402","DOI":"10.1038\/s41598-019-56013-w","article-title":"Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib111","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00193-2022","article-title":"Interferon-\u03b3 release assay screening in biologics: safe and reliable, but not perfect","volume":"8","author":"Cafferkey","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jinf.2026.106840_bib112","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.918901","article-title":"Abdominal Tuberculosis Mimicking Cancer Clinically and on Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Imaging: A Two-Case Series","volume":"21","author":"Di Renzo","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jinf.2026.106840_bib113","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"Targeted tuberculin testing and treatment of latent tuberculosis infection","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.jinf.2026.106840_bib114","first-page":"609","article-title":"Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy","volume":"32","author":"Mok","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejim.2017.05.020","article-title":"Nation-based case-control study investigating the relationship between oral corticosteroids use and pulmonary tuberculosis","volume":"43","author":"Lai","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jinf.2026.106840_bib116","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2169\/internalmedicine.41.1103","article-title":"Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy","volume":"41","author":"Kobashi","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.jinf.2026.106840_bib117","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s10067-018-4073-7","article-title":"Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study","volume":"37","author":"Suda","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jinf.2026.106840_bib118","doi-asserted-by":"crossref","first-page":"319","DOI":"10.47276\/lr.74.4.319","article-title":"Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials","volume":"74","author":"Richardus","year":"2003","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jinf.2026.106840_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jinf.2026.106840_bib120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1159\/000525980","article-title":"Inhaled Corticosteroids and Mycobacterial Infection in Patients with Chronic Airway Diseases: A Systematic Review and Meta-Analysis","volume":"101","author":"You","year":"2022","journal-title":"Respiration."},{"key":"10.1016\/j.jinf.2026.106840_bib121","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/thoraxjnl-2012-203175","article-title":"Use of inhaled corticosteroids and the risk of tuberculosis","volume":"68","author":"Lee","year":"2013","journal-title":"Thorax."},{"key":"10.1016\/j.jinf.2026.106840_bib122","author":"Disease GIfCOL","year":"2026","journal-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Prevention of Chronic Obstructive Pulmonary Disease"},{"key":"10.1016\/j.jinf.2026.106840_bib123","first-page":"152","article-title":"Analysis on related factors of pulmonary infection in patients with multiple Myeloma Treated with Bortezomib","volume":"29","author":"Li","year":"2021","journal-title":"J Exp Hematol"},{"key":"10.1016\/j.jinf.2026.106840_bib124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:25:55Z","timestamp":1792614355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0163445326001660"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106840","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification for tuberculosis reactivation in patients receiving biological and non-biological immunomodulators: A review of current literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106840"}}